Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company.

GlobeNewsWire • Dec 3, 2025

PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain

Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.

Zacks Investment Research • Dec 3, 2025

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. for patent infringement related to EXPAREL® (bupivacaine liposome injectable suspension).

GlobeNewsWire • Nov 26, 2025

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).

GlobeNewsWire • Nov 11, 2025

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

DOMA Controls 6.8% of Pacira Common Stock MIAMI , Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"), today sent a letter to the Board of Directors of Pacira (the "Board") urging the Board to hire bankers and conduct a full sale process of the company.  The letter can be downloaded here.

PRNewsWire • Nov 11, 2025

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Commercial Officer Shawn Cross - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Dennis Ding John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Pacira BioSciences Third Quarter Earnings Conference Call.

Seeking Alpha • Nov 7, 2025

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

GlobeNewsWire • Nov 6, 2025

Pacira (PCRX) Tops Q3 Earnings Estimates

Pacira (PCRX) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.79 per share a year ago.

Zacks Investment Research • Nov 7, 2025

Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 7, 2025

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has concluded patient enrollment in Part A of its Phase 2 ASCEND study evaluating PCRX-201 (enekinragene inzadenovec) for the treatment of osteoarthritis (OA) of the knee.

GlobeNewsWire • Nov 5, 2025